Daily supplementation with Akkermansia mucinivella Probiotics significantly improved fasting blood glucose, postprandial glucose, and hemoglobin A1c after 60 days.
These are the results of a new placebo-controlled study of 60 people with diabetes. The results strengthen the case for the clinical use of Akkermansia in the management of people at high risk of developing type 2 diabetes (T2D).
“Akkermansia mucinivella It alleviates features of T2D such as insulin resistance and metabolic syndrome by enhancing glucose, lipid, and bile acid metabolism. Its metabolite propionate stimulates GLP-1 secretion to enhance insulin release and suppress appetite, while P9 protein together with ICAM-2 activates GLP-1 pathways. Prabhu Rajagopalan and colleagues report Who did the study?
Changes in beneficial biomarkers seen among probiotic-treated subjects were accompanied by significant reductions in body weight, body mass index (BMI), and waist circumference. Treated patients also showed a statistically significant reduction in diastolic blood pressure compared with the placebo group, although there were no changes in systolic pressure, total cholesterol, LDL, or HDL.
Growing evidence
The new trial relies on previous evidence indicating this A. muciniphila It can affect human metabolism in ways that will reduce the risk of diabetes.
Population studies have shown that levels of A. muciniphila– These are mucin-degrading bacteria that make up up to 3-5% of the gut microbiota – and are inversely associated with obesity, prediabetes, and dyslipidemia. Animal studies indicate that A. muciniphila Supplementation can improve insulin sensitivity, glucose tolerance, and lipid profiles in rodents fed a high-fat diet.
precedent Human study proof of concept
showed that compared with placebo, taking Akkermansia daily over 3 months improved insulin sensitivity by 28.6%, reduced blood insulin by 34.1%, and reduced total cholesterol by 8.7% in a group of overweight/obese subjects. In that study there was also a small but non-significant reduction in body weight and fat mass.
Current study This was done by researchers at an Indian natural products company called Vidya, To test the effectiveness of a new Akkermansia-based probiotic called NuGensia.
Pre-diabetic cohort
They initially recruited 143 men and women between the ages of 31 and 60 who were diagnosed as having prediabetes according to current statistics. American Diabetes Association standards (A1c 5.7-6.4%; fasting blood glucose 100-125 mg/dL) and 2-hour OGTT blood glucose 140-199 mg/dL). Of this original group, 83 people were excluded because of concurrent high blood pressure, gastrointestinal disease, liver or kidney problems, or immunocompromised conditions.
The 60 participants were randomly assigned to take a daily oral probiotic supplement containing Vidya’s patented strain of the organism. A. muciniphila (10B CFU daily) or maltodextrin placebo. The treatment period was 60 days, after which participants underwent a full assessment of vital signs and biometrics.
At baseline, the placebo and probiotic groups were generally comparable on all key measures of glucose and lipid metabolism. By day 60, there were a number of significant and statistically significant changes.
Meaningful weight loss
The probiotic group showed significantly lower fasting glucose levels (109.4±14.6 vs. 113.0±14.9 mg/dL; p=0.0338), as well as lower postprandial glucose (131.7±25.5 vs. 145.7±25.4 mg/dL; p=0.0373). Notably, mean HbA1c was approximately 14% lower among those taking probiotics (4.78 ± 0.17 vs. 5.55 ± 0.64%; p = 0.0428).
Triglyceride levels (TGL) did not change among patients treated with placebo, but decreased significantly in the probiotics group. At day 60, mean TGL was 122.4 ± 42.4 mg/dL after probiotic treatment, versus 151.1 ± 54.9 mg/dL in the placebo group. That’s a 19% decrease.
However, there were no other significant changes in lipid markers.
Akkermansia supplements have been associated with significant weight loss. Patients who took probiotics lost an average of 4.4 kg over the 60-day period, from 68.55 kg at baseline to 64.15 kg at the end of the study. This represents a 6.4% reduction, from just probiotics without any nutritional or exercise interventions.
Not surprisingly, this was associated with a statistically significant decrease in BMI and a decrease in average waist circumference.
In contrast, there was a slight weight gain of 0.69 among placebo patients over the 60-day treatment period, with no significant change in body mass index or waist circumference.
No adverse effects were reported by the 30 participants who took the probiotics. This reflects the conclusion of a meta-analysis of previous Akkermansia studies reporting only mild gastrointestinal effects with an incidence of less than 5%.
“Therapeutic microbe”
“Through our study we demonstrated that oral nutritional supplements contain… Akkermansia mucinivella “Glycemic control, triglyceride levels, central obesity, and diastolic blood pressure in adults with diabetes were significantly improved over 60 days, with an optimal safety profile,” Dr. Rajagopalan and colleagues wrote.
They attributed the decrease in diastolic pressure “to decreased visceral adiposity and inflammation, mechanisms that have been validated in studies of microbial obesity.”
Akkermansia mucinivella It produces a number of metabolites that enhance glucose, lipid, and bile acid metabolism in humans. Propionate, a major compound produced by this organism, stimulates the secretion of GLP-1 which leads to insulin release and appetite suppression.
Rajagopalan points out this A. muciniphila It also activates hepatic PI3K-Akt signaling, which improves glucose and lipid regulation, and affects a number of genes in intestinal cells. It reduces white adipose tissue, increases triglyceride clearance, and favorably alters bile acid metabolism.
The authors believe that these effects are multi-pathway A. muciniphila It should be considered a “therapeutic gut microbe,” and it deserves a place as an adjuvant strategy for improving cardiovascular health.
As with any clinical study funded and conducted by the Company, there is the potential for bias in favor of the Company’s products, and we should keep this in mind when considering the study’s conclusions. Moreover, the study included a rather small number of patients, at least by pharmaceutical standards, as well as a rather short treatment period, limitations that the authors clearly acknowledge.
However, this new study makes a strong case for Vidya’s inclusion A. muciniphila Probiotics in the care of people with metabolic dysregulation who are at higher risk of developing type 2 diabetes.
end
